Tumor growth and mouse body weight were assessed twice weekly.
(DOC 34 KB) 13550_2013_185_MOESM3_ESM.doc Additional file 3: Figure S3: Mouse body weight changes after treatment.
13550_2013_185_MOESM1_ESM.doc Additional file 1: Figure S1: Mouse body weight change after treatment with RIT alone or in combination with chemotherapy.
The results showed that irradiation of mouse brain with 2 Gy of 12C6+ ion or 60Co γ-ray significantly diminished mouse body weight and level of serum GH.
Data were corrected for the radioactivity decay and tail injected dose and normalised for the standard mouse body weight (20 g).
Animals were treated with analgesics (Temgesic® 0.1 mg/kg, mouse body weight 23.2 ± 1.9 g) and anaesthetised by isoflurane inhalation (3%, 200 mL/min).
Synergistic antitumor activity was also demonstrated in vivo without undue toxicity; no excessive loss in mouse body weight or overt pathology were observed at the effective doses.
Pre-exposure with a low-dose (0.05 Gy) of 12C6+ ion or 60Co γ-ray significantly alleviated reductions of mouse body weight and level of serum GH induced by a subsequent high-dose (2 Gy) irradiation.
The mice were given an intraperitoneal injection of 10 mg/kg body weight D-luciferin (Caliper Life Sciences, Hopkinton, MA) suspended in sterile PBS at a concentration of 15 mg/mL (100 μL luciferin solution/10 g mouse body weight).
Although the TG mouse body weight was reduced (Fig. S2B), PI4KIIα overexpression had little effect on food intake (Fig. S2C) or plasma cholesterol, triglyceride, LDL-c, and HDL-c content compared to WT littermates (Fig. S2D).
DiR-NDs and DiR-HFNDs were intravenously administered into HeLa tumor-bearing nude mice via tail veins at an equivalent dose of DiR-HCPT per kilogram mouse body weight.
